Tigo Energy Expands Predict+ for Utility Analytics as Platform Approaches 10X Annual Growth
10.2.2025 15:00:00 CET | Business Wire | Press release
Predict+ platform surpasses 140,000 meters under management globally, expands advanced feature set, and brings machine learning-powered energy consumption and production prediction to utilities in Europe and North America.
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a set of powerful enhancements to the Predict+ platform that gives utilities deep insight into grid demand, renewable generation, and energy market dynamics. Designed to enhance the accuracy, scalability, and robustness of energy forecasting with up to 97.5% accuracy through machine learning and artificial intelligence, the platform leverages smart meter consumption data to predict precise grid production and consumption forecasts. Predict+ helps energy providers streamline operations, reduce volatility, and maximize performance. Since the first quarter of 2024, the Predict+ platform has grown from 15,000 to 140,000 meters under management and covers a total of 600 GWh of energy today.
Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. The platform delivers actionable intelligence that improves load forecasting accuracy while reducing manual workload, with data intervals ranging from yearly, monthly, daily, and down to by-the-minute data resolution. Predict+ includes the following primary functional domains:
- Market Insights: an accurate view of the near-term energy market trends combined with customer-internal data in an easy to consume, customizable dashboard
- Customer Insights: a combination of market and cost data used to evaluate the financial impact of expanding into new markets or acquiring high-value customers
- Profit Analysis: predicts and documents actual revenues from end-customers with integrated billing and invoicing functions taking existing processes from days, down to minutes.
- Regulatory Support: automatically generates forecast plans and securely transmits the plans to regulatory agencies in select regions
“The Predict+ platform doesn't only allow our customers to lower operating costs and streamline workflows, it actually drives higher returns on investment and more resilient, intelligent renewable energy infrastructure,” said Zvi Alon, chief executive officer at Tigo Energy. “As Predict+ expands into Europe and North America, we are bringing machine learning to energy analytics and predictions to a new standard for energy forecasting. As energy generation becomes more diverse and markets become increasingly dynamic, Predict+ offers a competitive edge by bringing grid stability and true foresight to utility operators.”
Predict+ has the ability to quickly recalibrate demand and load forecasts in response to external disruptions—such as COVID-19 and extreme weather events—which gives grid operators a distinct competitive edge. Existing customers continue to validate the platform’s real-world value by expanding their usage, adding modules, and scaling capacity. Predict+ stands apart from traditional forecasting methods by leveraging advanced algorithms that reduce volatility, improve accuracy, and streamline operations, often outperforming legacy approaches like spreadsheets by up to 11%, with approximately 3% deviation from actual. By consistently delivering higher accuracy with reduced manual intervention, Predict+ has become a trusted solution for energy providers looking to optimize grid performance through forecasting.
To learn more about Predict+ or participate in a platform demonstration, contact the Tigo team here and select “Predict+ info/demo” in the subject menu.
About Tigo Energy
Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210484457/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom